ikkgamma

ikkgamma

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">IKBKG (NEMO)</th></tr>
<tr><td>Symbol</td><td>IKBKG</td></tr>
<tr><td>Alternative Symbol</td><td>NEMO, IKKγ</td></tr>
<tr><td>Full Name</td><td>Inhibitor of kappa B kinase gamma</td></tr>[@yamaoka1998]
<tr><td>Chromosome</td><td>Xq28</td></tr>[@rothwarf1998]
<tr><td>NCBI Gene ID</td><td>[8517](https://www.ncbi.nlm.nih.gov/gene/8517)</td></tr>
<tr><td>OMIM</td><td>[308400](https://omim.org/entry/308400)</td></tr>
<tr><td>Ensembl</td><td>[ENSG00000006022](https://www.ensembl.org/Homo_sapiens/ENSG00000006022)</td></tr>
<tr><td>UniProt</td><td>[Q9Y6K9](https://www.uniprot.org/uniprot/Q9Y6K9)</td></tr>
<tr><td>Protein Class</td><td>Regulatory subunit of IκB kinase complex</td></tr>
<tr><td>Tissue Expression</td><td>Ubiquitous (brain, immune cells)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ikkgamma

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">IKBKG (NEMO)</th></tr>
<tr><td>Symbol</td><td>IKBKG</td></tr>
<tr><td>Alternative Symbol</td><td>NEMO, IKKγ</td></tr>
<tr><td>Full Name</td><td>Inhibitor of kappa B kinase gamma</td></tr>[@yamaoka1998]
<tr><td>Chromosome</td><td>Xq28</td></tr>[@rothwarf1998]
<tr><td>NCBI Gene ID</td><td>[8517](https://www.ncbi.nlm.nih.gov/gene/8517)</td></tr>
<tr><td>OMIM</td><td>[308400](https://omim.org/entry/308400)</td></tr>
<tr><td>Ensembl</td><td>[ENSG00000006022](https://www.ensembl.org/Homo_sapiens/ENSG00000006022)</td></tr>
<tr><td>UniProt</td><td>[Q9Y6K9](https://www.uniprot.org/uniprot/Q9Y6K9)</td></tr>
<tr><td>Protein Class</td><td>Regulatory subunit of IκB kinase complex</td></tr>
<tr><td>Tissue Expression</td><td>Ubiquitous (brain, immune cells)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

IKBKG encodes Inhibitor of kappa B kinase gamma (IKKγ), also known as NEMO (NF-κB Essential Modulator). IKBKG is a critical regulatory subunit of the IκB kinase (IKK) complex, which plays a central role in activating the NF-κB transcription factor pathway. The IKK complex consists of two catalytic subunits (IKKα and IKKβ) and one regulatory subunit (IKKγ/NEMO). NF-κB is a key regulator of inflammation, cell survival, and immune responses—all processes critically involved in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

IKBKG is essential for coupling upstream signaling events to IKK activation through its scaffolding function and regulatory ubiquitin-binding activity[@karin2000]. Mutations in IKBKG cause Incontinentia Pigmenti (IP) in females and a spectrum of immune deficiencies in males, demonstrating its essential role in human biology.

Normal Function

IKK Complex Architecture

The IKK complex is the central hub for NF-κB activation[@israel2010]:

Structural Organization:

• IKKβ ( kinase subunit): The catalytic workhorse that phosphorylates IκBα
• IKKα ( kinase subunit): Has distinct functions in non-canonical NF-κB signaling
• IKBKG/NEMO (regulatory subunit): Scaffolds the complex and mediates upstream signal transduction

• N-terminal coiled-coil domain: Mediates dimerization and interaction with upstream kinases
• Leucine zipper domain: Required for complex assembly
• C-terminal zinc finger: Involved in ubiquitin binding

NF-κB Signaling Pathway

The NF-κB transcription factor family includes[@hayden2004]:

Canonical Pathway (IKBKG-dependent):

• Pro-inflammatory stimuli (TNF-α, IL-1β, LPS) activate receptor-associated kinases
• TRAF proteins generate M1-linked ubiquitin chains
• IKBKG binds these ubiquitin chains via its UBAN domain
• This brings TAK1 kinase to the IKK complex
• TAK1 phosphorylates and activates IKKβ
• IKKβ phosphorylates IκBα on Ser32 and Ser36
• Phosphorylated IκBα is ubiquitinated and degraded
• NF-κB (RelA:p50 dimer) translocates to the nucleus

• Activated by lymphotoxin, CD40, BAFF receptors
• Requires processing of p100 to p52
• Less dependent on IKBKG

Role in Neuroinflammation

NF-κB in the Central Nervous System

NF-κB signaling plays complex, context-dependent roles in the brain[@mattson2002][@kaltschmidt2002]:

Neuronal NF-κB:

• Low basal activity in healthy neurons
• Rapidly activated by excitatory neurotransmission (glutamate)
• Regulates expression of anti-apoptotic proteins (Bcl-2, Bcl-xL)
• Controls neuroprotective genes (MnSOD, A1AT)
• Activity declines with age

• High basal activity in astrocytes and microglia
• Mediates inflammatory cytokine production
• Critical for neuroinflammation in disease states
• Microglial NF-κB drives chronic neuroinflammation

IKBKG in Alzheimer's Disease

NF-κB activation is a consistent finding in AD brain[@yang2018][@liu2021]:

Evidence:

• Elevated NF-κB activity in AD hippocampus and cortex
• Correlates with disease severity
• Found in both neurons and glia

• Amyloid-beta effects: Aβ oligomers activate NF-κB through multiple receptors (RAGE, TLR4)
• Tau pathology: Hyperphosphorylated tau enhances NF-κB activation
• Oxidative stress: ROS directly activates IKK

• Increased production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
• Enhanced expression of COX-2 and iNOS
• Recruitment of additional microglia
• Synaptic dysfunction through inflammatory mediators

• Polymorphisms in NF-κB pathway genes associated with AD risk[@romano2010]
• IKBKG expression altered in AD brain
• Meta-analyses suggest modest genetic associations

IKBKG in Parkinson's Disease

NF-κB activation contributes to dopaminergic neuron death in PD[@song2014]:

Evidence:

• Elevated NF-κB in substantia nigra of PD patients
• Correlates with disease progression
• Found in microglia surrounding Lewy bodies

• α-Synuclein pathology: Aggregated α-synuclein activates NF-κB in microglia
• Mitochondrial dysfunction: Complex I inhibition activates NF-κB
• Oxidative stress: 6-OHDA and MPTP models show NF-κB involvement

• Conditional knockout in mice causes dopaminergic neurodegeneration[@henes2018]
• Microglial activation and neuroinflammation
• This suggests IKBKG may have cell-type specific protective functions

IKBKG in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS):

• NF-κB activated in motor neurons and glia
• Contributes to inflammation and excitotoxicity
• IKBKG expression upregulated in SOD1 models

• NF-κB mediates demyelination and inflammation
• IKK inhibition is protective in models

• NF-κB activation contributes to secondary damage[@zhang2019]
• IKBKG involved in inflammatory response

Therapeutic Implications

IKK/NF-κB as Drug Target

Targeting the IKK/NF-κB pathway is being explored for neurodegeneration[@chen2022]:

| Strategy | Compound/Approach | Stage | Status |
|----------|-------------------|-------|--------|
| IKKβ inhibitors | MLN120B, Bay 11-7082 | Preclinical | Block neuroinflammation |
| NF-κB inhibitors | Pyrrolidine dithiocarbamate | Preclinical | Reduce cytokine production |
| Ubiquitin modulators | TAK-243 | Research | Block upstream activation |
| Gene therapy | siRNA targeting IKBKG | Early | Selective inhibition |

Challenges:

• NF-κB has both protective and destructive roles
• Systemic inhibition causes immunosuppression
• Cell-type specific targeting needed

Neuroprotective Strategies

Regulation of IKBKG

Transcriptional Control

• Constitutively expressed in most tissues
• NF-κB can regulate its own expression (feedback)
• Regulated by glucocorticoids and other anti-inflammatory signals

Post-translational Modifications

• Phosphorylation: Multiple sites regulate complex assembly
• Ubiquitination: K63-linked chains scaffold signaling complexes
• SUMOylation: Affects subcellular localization

Protein Interactions

| Partner | Function | Reference |
|---------|----------|-----------|
| IKKα/IKKβ | Core complex assembly | [@rothwarf1998] |
| TAK1 | Upstream kinase | [@karin2000] |
| TRAF2/6 | Ubiquitin ligases | [@chen2005] |
| NEMO-like protein (NEMO-L) | Alternative spliced form | [@israel2010] |

Clinical Genetics

IKBKG Mutations

Incontinentia Pigmenti (IP):

• X-linked dominant, lethal in males
• Skin lesions, neurological symptoms, ocular defects
• Caused by truncating mutations in females

• Males with hypomorphic mutations
• Ectodermal dysplasia, immunodeficiency (EDA-ID)
• Impaired NF-κB activation in immune cells

Research Tools

Mouse Models:

• Ikbkg conditional knockouts (Nes-Cre, CamKII-Cre)
• Ikkb conditional knockouts for comparative studies
• Transgenic NF-κB reporter lines

• Primary neurons and astrocytes
• Microglial cell lines (BV2, RAW264.7)
• Induced pluripotent stem cells (iPSCs)

Key Publications

Cell-Type Specific Functions

Neuronal IKBKG

Neurons rely on IKBKG-mediated NF-κB signaling for critical functions:

Synaptic Plasticity:

• NF-κB regulates expression of AMPA and NMDA receptor subunits
• Activity-dependent IKK activation in dendritic spines
• CREB phosphorylation through NF-κB-dependent gene expression
• Long-term potentiation (LTP) requires IKBKG function

• NF-κB-dependent anti-apoptotic gene expression (Bcl-2, Bcl-xL)
• Neurotrophin signaling (BDNF, NGF) requires IKBKG
• Protection against excitotoxicity through NF-κB
• Age-related decline in neuronal NF-κB contributes to vulnerability

Microglial IKBKG

Microglia show high basal IKK activity:

Inflammatory Response:

• TLR-mediated IKK activation triggers cytokine production
• IKBKG required for full inflammatory response
• Shapes neuroinflammatory environment in disease

• NF-κB regulates complement proteins and scavenger receptors
• IKBKG affects clearance of debris and pathological proteins
• Implications for Aβ and α-synuclein clearance

Astrocytic IKBKG

Astrocytes use IKBKG in distinct ways:

Reactive Astrogliosis:

• NF-κB drives expression of GFAP and other reactivity markers
• IKBKG mediates cytokine-induced astrocyte activation
• Contributes to glial scar formation

• NF-κB regulates glucose transporters in astrocytes
• IKBKG affects lactate production and transport
• Implications for neuronal energy support

Molecular Mechanisms

IKK Complex Activation

The activation cascade involves:

Step 1 - Receptor Activation:

• TNF receptor, IL-1R, TLR families activate
• Recruitment of adaptor proteins (MyD88, TRADD, TRAF)

• TRAF6 generates K63-linked ubiquitin chains
• Linear ubiquitin chain assembly complex (LUBAC) adds M1 chains
• IKBKG UBAN domain binds these chains

• Ubiquitin chains bring TAK1 kinase to the complex
• TAK1 phosphorylates IKKβ on activation loop (Ser177/181)
• IKKβ activation requires IKBKG for proper orientation

• Activated IKK phosphorylates IκBα
• Phosphorylated IκBα is polyubiquitinated and degraded
• NF-κB dimers released and translocate to nucleus

Downstream Signaling Effects

Once activated, NF-κB regulates:

Pro-inflammatory Genes:

• Cytokines: IL-1β, IL-6, TNF-α, IL-8
• Chemokines: CCL2, CXCL10
• Enzymes: COX-2, iNOS

• Bcl-2 family members
• c-IAP1/2, XIAP
• A1, A20

• Complement components
• Coagulation factors
• Transport proteins

Disease-Specific Mechanisms

Alzheimer's Disease Pathogenesis

Ikbkg-mediated NF-κB in AD involves:

Amyloid-Beta Activation:

• Aβ oligomers bind to multiple receptors (RAGE, TLR4, nAChR)
• Each receptor pathway converges on IKK
• Chronic low-level NF-κB activation in AD brain
• Creates feed-forward inflammatory loop

• Phosphorylated tau can activate NF-κB
• NF-κB can influence tau kinases (GSK3β, CDK5)
• Creates amplification cycle

• NF-κB regulates synaptic protein expression
• Chronic inflammation reduces synaptic plasticity
• Contributes to memory deficits

Parkinson's Disease Mechanisms

Ikbkg in PD shows cell-type specificity:

Dopaminergic Neurons:

• IKKγ deficiency leads to spontaneous degeneration
• Mitochondrial complex I inhibitors activate IKK
• α-Synuclein aggregation triggers NF-κB

• Chronic microglial NF-κB activation
• Pro-inflammatory cytokine release
• Progressive dopaminergic loss

Multiple Sclerosis and Demyelination

NF-κB contributes to MS pathogenesis:

Inflammatory Demyelination:

• NF-κB in oligodendrocyte precursor cells
• Affects differentiation and survival
• Contributes to remyelination failure

• T-cell NF-κB drives myelin antigen responses
• B-cell NF-κB affects antibody production

Therapeutic Strategies

IKKβ vs IKBKG Targeting

Rationale for IKKβ Selectivity:

• IKBKG essential for multiple cell types
• Complete inhibition causes immunosuppression
• IKKβ is the catalytic subunit with more specific role

• MLN120B: Prevents IKKβ phosphorylation
• Bay 11-7082: Blocks IκBα phosphorylation
• TPCA-1: ATP-competitive inhibition

Cell-Type Specific Approaches

Microglia-Targeted Delivery:

• CCR2-targeted nanoparticles
• Galectin-3-mediated delivery
• MiniSOG-based photochemical inhibition

• AAV-mediated siRNA delivery
• Synaptic activity-responsive promoters
• Activity-dependent release systems

Combination Approaches

NF-κB + Anti-inflammatory:

• IL-1 receptor antagonists
• TNF-α neutralizing antibodies
• COX-2 inhibitors

• Antioxidants (NAC, Edaravone)
• Mitochondrial protectants
• Neurotrophic factors

Research Tools and Models

Genetic Models

Knockout Models:

• Ikbkg global knockout (embryonic lethal in mice)
• Conditional knockouts (Nes-Cre, CamKII-Cre, CD68-Cre)
• Tissue-specific deletion strategies

• NF-κB reporter lines (GFP, luciferase)
• IKK activity monitoring mice
• Disease model crosses

Cellular Models

Primary Cells:

• Primary cortical neurons
• Primary microglia and astrocytes
• Brain organoids

• Patient-derived neurons
• Isogenic lines with specific mutations
• Disease modeling with NF-κB readouts

Therapeutic Screening

In Vitro Screens:

• IKKβ activity assays
• NF-κB reporter cell lines
• Primary neuron survival assays

• Behavioral testing in mouse models
• Neuropathology assessment
• Biomarker measurement

Genetic Considerations

IKBKG in Neurodegeneration

Genetic Variants:

• No known AD/PD-causing mutations
• Common polymorphisms may affect NF-κB activation
• Expression quantitative trait loci (eQTLs) in brain

• Stratification based on NF-κB pathway genotypes
• Personalized approaches based on genetic background
• Pharmacogenomics of IKK inhibitors

Epigenetic Regulation

DNA Methylation:

• IKBKG promoter methylation patterns
• Changes in disease states
• Potential biomarker applications

• NF-κB p65 acetylation status
• Chromatin accessibility at NF-κB targets
• Therapeutic modulation possibilities

Biomarker Potential

NF-κB Activity Markers

Peripheral Biomarkers:

• Cytokine levels in CSF and blood
• NF-κB DNA-binding activity in PBMCs
• Phosphorylated IKK in circulating cells

• TSPO PET for microglial activation
• Correlations with NF-κB pathway activity
• Treatment response monitoring

Clinical Applications

Diagnostic Markers:

• Differentiate disease subtypes
• Identify patients with high NF-κB activity
• Early detection possibilities

• Disease progression prediction
• Treatment response forecasting
• Biomarker-driven patient selection

See Also

• [NF-κB Signaling Pathway](/mechanisms/nf-kappa-b-signaling)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [TNF-alpha Signaling](/mechanisms/tnf-alpha-signaling)
• [Microglial Activation](/cell-types/microglia)

External Links

• [NCBI Gene: IKBKG](https://www.ncbi.nlm.nih.gov/gene/8517)
• [UniProt: Q9Y6K9](https://www.uniprot.org/uniprot/Q9Y6K9)
• [OMIM: 308400](https://omim.org/entry/308400)
• [Ensembl: ENSG00000006022](https://www.ensembl.org/Homo_sapiens/ENSG00000006022)
• [PubMed: NF-κB neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=NF-κB+neurodegeneration+IKBKG)